ALEXANDRIA, Va. – An influx of new oral cancer drugs provides patients with a more convenient and less invasive way to take medication, but such treatments are often associated with adherence challenges and medical errors. New research shows that the addition of an in-house specialty pharmacy at a cancer center in New Haven, Connecticut, improved overall quality of care for patients, reduced the amount of time it took patients to receive their medication, and prevented errors associated with filling, dispensing, and taking oral chemotherapy. Authors will present their findings at the American Society of Clinical Oncology’s (ASCO) upcoming Quality Care Symposium, taking place March 3-4, in Orlando, Florida.
ALEXANDRIA, Va. – As an increasing number of patients look to the internet for cancer information, researchers from the University of Alabama found that the websites of many National Cancer Institute (NCI)-designated cancer centers lack sufficient information to help patients with breast cancer understand all their treatment options and make well-informed decisions. It also found they are not fully accessible to Spanish-speaking patients and those using mobile devices. In contrast, websites of the NCI and the Susan G. Komen® had high-quality patient information. Researchers will present their findings at the American Society of Clinical Oncology’s (ASCO) upcoming Quality Care Symposium, taking place March 3-4, in Orlando, Florida.
ALEXANDRIA, Va. – A new analysis of data from the U.S. Military Health System finds that mood and adjustment disorders such as anxiety and depression were strong predictors of the annual number of outpatient visits, hospital admissions, and number of days in the hospital for patients with breast and prostate cancer. The study also found that between 2007 and 2014, mood and adjustment disorders increased 7% (21% to 28%) among breast cancer patients and 4% (9% to 13%) among prostate cancer patients. However, during this period the rate at which depression increased was identical for both groups. Authors will present their findings at the American Society of Clinical Oncology’s (ASCO) upcoming Quality Care Symposium, taking place March 3-4, in Orlando, Florida.
ALEXANDRIA, Va. –– The embargo has lifted on all abstracts from the 2017 Quality Care Symposium. Journalists may now report on these abstracts, which are publicly available at abstracts.asco.org.
ALEXANDRIA, Va. – CancerLinQ LLC and the American Society for Radiation Oncology (ASTRO) are partnering to bring radiation oncology expertise to CancerLinQ® and improve the care of cancer patients nationwide. ASTRO will provide guidance for the development of the CancerLinQ® platform to ensure that the system captures more relevant patient data to drive actionable decision-making in cancer care, as well as to advance public policy and population health issues. ASTRO also will use insights from CancerLinQ Discovery™ to improve the care of patients receiving radiation therapy.
ORLANDO, Fla. - Seven studies exploring clinical and translational research in immuno-oncology and its implications on patient care will be presented at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium. These noteworthy abstracts provide new insights on evaluating and predicting both responses and outcomes in patients treated with immunotherapy.
ALEXANDRIA, Va. – A large population-based study suggests that the utility of certain types of biomarkers, known as tumor-infiltrating lymphocytes (TILs), to predict colorectal cancer survival depends on where the tumor originates in the body. Although prior research has shown an association between high TIL density and longer survival for patients with colorectal cancers, according to the authors this study is the first to examine the prognostic impact of TILs in regards to tumor location. The study will be presented at the upcoming 2017 ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando.
ALEXANDRIA, Va. – Researchers have found a link between microbes in the gut (the microbiome) and response to immunotherapy. In the study, the ability of patients with advanced melanoma to respond to PD-1 immune checkpoint inhibitors depended on the presence of a diverse microbiome as well as specific bacterial species. The study will be presented at the upcoming 2017 ASCO-SITC Clinical Immuno-Oncology Symposium in Orlando.
ORLANDO – Five studies exploring key issues in the treatment of genitourinary cancers will be presented at the 2017 Genitourinary Cancers Symposium, taking place February 16-18 at Rosen Shingle Creek in Orlando, Florida. These noteworthy abstracts investigate several approaches to the treatment and management of prostate cancer, bladder cancer, and advanced kidney cancer.
ALEXANDRIA, Va. – A new retrospective analysis suggests that immunotherapy may be less effective in patients who receive antibiotics less than a month before starting treatment. In the study, cancer worsened more quickly in such patients than in those who did not receive antibiotics (median progression-free survival 2.3 months vs. 8.1 months). The study will be presented at the upcoming 2017 Genitourinary Cancers Symposium in Orlando.
ALEXANDRIA, Va. – Early findings from a new study appear to challenge the current standard practice for immune checkpoint inhibitor therapy – continuing treatment until cancer worsens. Among patients with advanced kidney cancer who stopped PD1/PD-L1 immunotherapy early due to side effects, 42% had a durable response, meaning they were able to remain off additional systemic therapy for 6 months or more. More broadly, this insight may help alleviate some patients’ concerns about the impact of discontinuing immunotherapy. The study will be presented at the upcoming 2017 Genitourinary Cancers Symposium in Orlando.
ALEXANDRIA, Va. – Analysis of free-floating cancer DNA from blood samples has yielded leads for new prostate cancer treatment targets. Using a commercially available “liquid biopsy” test in patients with advanced prostate cancer, researchers found a number of genetic changes in cell-free, circulating tumor DNA (ctDNA). Cell-free ctDNA is tumor DNA that is circulating freely in the patient’s bloodstream. The study will be presented at the upcoming 2017 Genitourinary Cancers Symposium in Orlando.
“ASCO congratulates Representative Tom Price for his confirmation as Secretary of the U.S. Department of Health and Human Services (HHS). Secretary Price has a unique opportunity to shape the availability and quality of care for millions of people with cancer and maintain the nation’s leadership in biomedical research."
ALEXANDRIA, Va. – CancerLinQ LLC, a wholly owned nonprofit subsidiary of the American Society of Clinical Oncology (ASCO®), has announced that the University of Virginia (UVA) Cancer Center has signed an agreement to participate in the CancerLinQ® platform.
A new study suggests that weight loss could decrease the risk of endometrial cancer in postmenopausal women by as much as 29 to 56%. Researchers observed that the benefit was greatest for obese women who actively worked to lose weight. These findings, which draw from the Women’s Health Initiative (WHI) study data, were published online today in the Journal of Clinical Oncology.